NCT06073184View on ClinicalTrials.gov

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 29, 2032

Conditions
Endometrial CancerAtypical Hyperplasia
Interventions
DRUG

Mounjaro

Weekly subcutaneous injection of 2.5mg tirzepatide at baseline with dose escalation by 2.5mg every 4 weeks to reach 15mg or the maximum tolerated dose, by Week 20

DRUG

Mirena

Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day

All Listed Sponsors
lead

University Health Network, Toronto

OTHER